Sanofi India on Tuesday said it has launched its diabetes drug Soliqua in the country. The company introduced the medication after receiving the marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) earlier last year. Soliqua is a once-daily injectable combination drug containing insulin, glargine 100 units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist.

赛诺菲印度公司周二表示，已在该国推出其糖尿病药物Soliqua。该公司在去年早些时候获得中央药物标准控制组织（CDSCO）的上市许可后推出了这种药物。Soliqua是一种每日一次的可注射联合药物，含有胰岛素，甘精胰岛素100单位/毫升，是一种长效基础胰岛素和利西那肽，一种GLP-1受体激动剂。

It is available at a therapy cost of Rs 1,850 per pen. 'The inclusion of Soliqua to our comprehensive diabetes portfolio (orals and injectables) eases therapy initiation, which helps those prescribed, keep their blood sugar in control more effectively,' Sanofi India Head Diabetes Business Unit Cyrus Aibara said in a statement.

它的治疗费用为每支笔1850卢比。”赛诺菲印度糖尿病业务部门负责人赛勒斯·艾巴拉（CyrusAibara）在一份声明中说，将Soliqua纳入我们的综合糖尿病产品组合（口服和注射）可以简化治疗的开始，这有助于处方患者更有效地控制血糖。

Soliqua is indicated as a treatment in adults with obesity and type 2 diabetes mellitus, to improve glycemic control as an adjunct to diet and exercise, in those who are insufficiently controlled on oral or injectable therapies.(You can now subscribe to our Economic Times WhatsApp channel)(You can now subscribe to our Economic Times WhatsApp channel).

Soliqua被认为是肥胖和2型糖尿病成年人的一种治疗方法，用于改善血糖控制，作为饮食和运动的辅助手段，用于口服或注射疗法控制不足的患者。（您现在可以订阅我们的经济时报WhatsApp频道）（您现在可以订阅我们的经济时报WhatsApp频道）。